Indirubin-5-sulfonic acid . sodium salt

Inhibitor of CDK and GSK



ALX-270-296-M001	1 mg	76.00 USD

ALX-270-296-M005	5 mg	324.00 USD

Inhibitor of cyclin-dependent kinases (CDKs), with selectivity for CDK1/cyclin B (IC₅₀=55nM), CDK2/cyclin A (IC₅₀=35nM), CDK2/cyclin E (IC₅₀=150nM), CDK4/cyclin D1 (IC₅₀=300nM), CDK5/p35 (IC₅₀=65nM) and GSK-3β (IC₅₀=280nM).

Product Specification

Alternative Name:	E226, Indirubin-5-sulphonate . Na

Formula:	C₁₆H₉N₂O₅S . Na

MW:	341.3 . 23.0

Purity:	≥95% (¹H-NMR)

Appearance:	Black powder.

Solubility:	Soluble in DMSO or water.

Long Term Storage:	-20°C

Please mouse over

Product Literature References

Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?: S. Leclerc, et al.; J. Biol. Chem. 276, 251 (2001), Abstract; Full Text

Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells: D. Marko, et al.; Br. J. Cancer 84, 283 (2001), Abstract;

Inhibitor binding to active and inactive cdk2. the crystal structure of cdk2-cyclin a/indirubin-5-sulphonate: T.G. Davies, et al.; Structure (Camb) 9, 389 (2001), Abstract;

Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases: R. Hoessel, et al.; Nat. Cell. Biol. 1, 60 (1999),